Cytek Biosciences Inc (CTKB)
Debt-to-equity ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Long-term debt | US$ in thousands | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 395,737 | 393,064 | 425,295 | 406,458 | -16,028 |
| Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | — |
December 31, 2024 calculation
Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $—K ÷ $395,737K
= 0.00
The debt-to-equity ratio of Cytek Biosciences Inc has been consistently at 0.00 from December 31, 2021, to December 31, 2024. This indicates that the company has no debt on its balance sheet during these years. A debt-to-equity ratio of 0.00 suggests that the company is financing its operations entirely through equity, which can be seen as a positive sign, as it means the company is not reliant on borrowed funds to support its growth and operations. This low debt level enhances the company's financial stability and may indicate a lower risk profile compared to companies with higher debt levels. However, it's essential to also consider other factors like the industry norms and the company's growth prospects to have a more comprehensive understanding of its financial position.
Peer comparison
Dec 31, 2024